← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Phasebio Pharmaceuticals, Inc.
Morrisville, NC
$3,487,390
Total funding
3
Grants
Funding over time
peak $1.5M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,487,390 · 3
By mechanism
R44$3,387,390 · 2
R43$100,000 · 1
Investigators at Phasebio Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension$1,249,307
R44 · FY2019 · HL
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension$1,247,966
R44 · FY2018 · HL
Low Cost Production of Recombinant Proteins$334,375
R44 · FY2006 · GM
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension$297,765
R44 · FY2018 · HL
Low Cost Production of Recombinant Proteins$257,977
R44 · FY2007 · GM
Smart DeltaPhase Tags for Purification of Recombinant Peptides$100,000
R43 · FY2006 · GM